Alethea Capital Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $110M | Sell |
649,114
-19,596
| -3% | -$3.38M | 56.28% | 1 |
|
|
2025
Q4 | $122M | Sell |
668,710
-2,173
| -0.3% | -$303K | 59.3% | 1 |
|
|
2025
Q3 | $81.5M | Buy |
670,883
+3,515
| +0.5% | +$396K | 52.34% | 1 |
|
|
2025
Q2 | $69.7M | Hold |
667,368
| – | – | 52.72% | 1 |
|
|
2025
Q1 | $77.8M | Sell |
667,368
-66,949
| -9% | -$7.63M | 58.07% | 1 |
|
|
2024
Q4 | $62.1M | Sell |
734,317
-4,186
| -0.6% | -$385K | 53.19% | 1 |
|
|
2024
Q3 | $66.4M | Sell |
738,503
-2,385
| -0.3% | -$208K | 47.94% | 1 |
|
|
2024
Q2 | $59.6M | Buy |
740,888
+97
| +0% | +$7.18K | 45.25% | 1 |
|
|
2024
Q1 | $59.1M | Sell |
740,791
-11,253
| -1% | -$945K | 48.02% | 1 |
|
|
2023
Q4 | $59.9M | Sell |
752,044
-6,750
| -0.9% | -$451K | 69.06% | 1 |
|
|
2023
Q3 | $53M | Sell |
758,794
-1,150
| -0.2% | -$86K | 65.14% | 1 |
|
|
2023
Q2 | $54.6M | Sell |
759,944
-25,739
| -3% | -$1.9M | 58.4% | 1 |
|
|
2023
Q1 | $48.5M | Hold |
785,683
| – | – | 51.17% | 1 |
|
|
2022
Q4 | $60.6M | Sell |
785,683
-2,580
| -0.3% | -$154K | 58.09% | 1 |
|
|
2022
Q3 | $35.2M | Sell |
788,263
-1,550
| -0.2% | -$77.5K | 44.43% | 1 |
|
|
2022
Q2 | $30.3M | Sell |
789,813
-253,346
| -24% | -$8.01M | 37.87% | 1 |
|
|
2022
Q1 | $43.2M | Sell |
1,043,159
-80,770
| -7% | -$2.5M | 39.06% | 1 |
|
|
2021
Q4 | $42.5M | Sell |
1,123,929
-8,716
| -0.8% | -$321K | 36.04% | 1 |
|
|
2021
Q3 | $37.3M | Buy |
1,132,645
+121,700
| +12% | +$4.74M | 32.87% | 1 |
|
|
2021
Q2 | $68.2M | Sell |
1,010,945
-1,258
| -0.1% | -$75.5K | 42.91% | 1 |
|
|
2021
Q1 | $57.3M | Buy |
1,012,203
+2,404
| +0.2% | +$169K | 34.96% | 1 |
|
|
2020
Q4 | $82.3M | Buy |
1,009,799
+668
| +0.1% | +$50K | 41.25% | 1 |
|
|
2020
Q3 | $71.9M | Buy |
1,009,131
+623
| +0.1% | +$48.5K | 48.66% | 1 |
|
|
2020
Q2 | $83M | Buy |
1,008,508
+16,754
| +2% | +$1.29M | 48.53% | 1 |
|
|
2020
Q1 | $58.3M | Sell |
991,754
-8,826
| -0.9% | -$719K | 37.79% | 1 |
|
|
2019
Q4 | $103M | Sell |
1,000,580
-301,766
| -23% | -$12.2M | 44.36% | 1 |
|
|
2019
Q3 | $26.4M | Hold |
1,302,346
| – | – | 16.69% | 2 |
|
|
2019
Q2 | $33.5M | Buy |
1,302,346
+161,952
| +14% | +$3.25M | 21.84% | 2 |
|
|
2019
Q1 | $16.2M | Buy |
1,140,394
+231,965
| +26% | +$2.15M | 11.55% | 2 |
|
|
2018
Q4 | $2.56M | Buy |
908,429
+360,986
| +66% | +$1.19M | 3.73% | 4 |
|
|
2018
Q3 | $1.89M | Buy |
547,443
+276,620
| +102% | +$820K | 2.83% | 8 |
|
|
2018
Q2 | $867K | Buy |
270,823
+154,323
| +132% | +$478K | 1.48% | 12 |
|
|
2018
Q1 | $285K | Hold |
116,500
| – | – | 0.39% | 70 |
|
|
2017
Q4 | $652K | Buy |
+116,500
| New | +$588K | 1.04% | 30 |
|
Other funds holding AXSM
VPM
VCM
DTC
Alethea Capital Management's AXSM Position: Q1 2026 in Review
Alethea Capital Management reduced its Axsome Therapeutics (AXSM) stake by 2.9% in Q1 2026, selling an estimated $3.38M and leaving 649,114 shares worth $110M. The position accounts for 56.28% of the portfolio, ranked #1.
Alethea Capital Management first reported a position in AXSM in Q4 2017 and has held it in 34 quarters since. The position peaked at $122M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Alethea Capital Management held 649,114 shares of Axsome Therapeutics worth $110M as of Q1 2026.
- Alethea Capital Management sold 19,596 Axsome Therapeutics shares in Q1 2026, an estimated $3.38M.
- Axsome Therapeutics made up 56.28% of Alethea Capital Management's portfolio in Q1 2026, its #1 holding.
- Alethea Capital Management first reported a position in Axsome Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Alethea Capital Management's Axsome Therapeutics position peaked at $122M in Q4 2025.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Alethea Capital Management's 13F filing for Q1 2026, filed 13 May 2026.